Biotech Investing: FDA One Pivotal Trial and 2Q Outlook | Biotech Bulls & Breakthroughs

Today's episode is brought to you by scientist.com, the life science industry's leading R and D orchestration platform. Scientist.com gives researchers instant access to thousands of pre vetted suppliers, saving time, reducing costs, and accelerating innovation. Hi. I'm John Galliano, senior director of BioPharm Catalyst. Hello. I'm Chef, known as Chef Station, a twenty year vet in trading biotech stocks. And this is biotech bulls and breakthroughs. Biopharm Catalyst is not a registered investment advisory firm, and the views on this podcast are not intended to be financial advice. Guests on this podcast may hold the stocks discussed in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions. Good morning, good afternoon, good evening, depending on, where and when you're joining us from. Welcome once again to another episode of biotech bulls and breakthroughs. Today is Tuesday, 03/24/2026. We are very, very close, about seven days away from the end of the quarter. Certainly been a very exciting quarter. And, as always, we're really excited to have Shef back on with us, this month to discuss, kind of his views on the market and what catalyst we have coming up, before the end of the quarter and into next quarter, and what he's excited about. So, Shef, welcome back, man, as always. Thank you. It's I mean, this has been a great, it's been a great year already. And, even with volatility that we're seeing, it's, you know, we still see good data gets rewarded. And, you know, we're we're seeing that, as we near the end of the first quarter. It's it's been pretty pretty strong. Absolutely. And, you know, I think there's a lot of there's been a lot of talk in the news lately about this kind of idea of selective optimism, so to speak. So kind of like the idea that, you know, things have obviously the XBAI has done extremely well in, you know, this past month. There's we've seen a little bit more volatility. And if you take a look at what the analysts have to say, you know, a lot of them kinda feel that it's not really a market crash, but just sort of, you know, kinda sort of general pullback, we'll say. And, you know, given some of the, uptick that we've seen in m and a activity as well as IPO activity, I think that there's a general consensus that sort of that the days of the the biotech winter are kinda behind us. Even if we do experience some volatility, that's obviously gonna be the case. We've got a lot of, you know, geopolitical things going on, and so, you're gonna have a little bit of that no matter what industry or sector you look at, inclusive of, you know, the S and P 500 itself. So, I think we're we're in a really good spot. Obviously, for us, …